Peter J. Arduini, President and CEO of GE HealthCare, Named Chair of AdvaMed Board of Directors

AdvaMed logo

December 11, 2023 | WASHINGTON, D.C.,  – Today, AdvaMed, the Medtech Association, announced that Peter J. Arduini, president and CEO of GE HealthCare, will become the Chair of the AdvaMed Board of Directors.

“The entire board and the global industry AdvaMed represents are very excited to have Peter as our new Board Chair during this critical time for medtech. Artificial Intelligence, imaging and digital technology represent important areas of innovation that can significantly accelerate diagnosis and improve the personalization of patient care. Peter’s proven record of leadership across more than three decades in medtech and imaging will enable him to advance AdvaMed’s goal of achieving healthier lives and healthier communities around the world. I look forward to working with him,” said AdvaMed President and CEO Scott Whitaker, who also serves as President of the AdvaMed Board of Directors.

Arduini said, “I appreciate the confidence my fellow AdvaMed Board members have placed in me as the Board’s new chair.  Through Scott’s leadership, AdvaMed has become a unifying voice for our industry to foster growth and innovative new solutions for patients, providers and health systems. The medical technology industry is at the forefront of defining the future of healthcare through smart devices, diagnostics and digital solutions that can enable earlier and more precise diagnoses, targeted treatments and improved patient outcomes. We need policies that keep pace with innovation, while fostering the highest ethical standards that improve patient access to the best care possible. With the promise of artificial intelligence and the interconnectivity of medical technologies, there has never been a more important time in our history to make profound and lasting changes in the delivery of care for patients.” 

Arduini has been president and chief executive officer of GE HealthCare, a global medical technology, pharmaceutical diagnostics, and digital solutions innovator, since January 2022.  He previously served as president and chief executive officer of Integra LifeSciences Holdings Corporation, corporate vice president and president of Medication Delivery, Baxter Healthcare, from 2005 to 2010. He previously spent 15 years at GE Healthcare where in a variety of management roles for domestic and global businesses, culminating in leading the global functional imaging business. Arduini also serves on the Boards of Directors of GE HealthCare, Bristol Myers Squibb and the National Italian American Foundation.

In the wake of former AdvaMed Chair Ashley McEvoy’s departure from Johnson & Johnson Medtech in October, Arduini stepped in to serve as interim chair over the past several weeks. The full Board elected him unanimously to a two-year term, which began immediately Friday.

Arduini  will unveil his priorities as AdvaMed Chair in early 2024.

December 10, 2025
Georgia Life Sciences has joined 43 state and regional life sciences organizations in signing a national Council of State Bioscience Associations (CSBA) letter calling on Congress to take immediate action on three bipartisan policy priorities that are essential to sustaining U.S. leadership in biomedical innovation and supporting patients nationwide. With Congress back in session and several critical programs at risk of expiring, the letter urges congressional leaders to advance the following provisions without delay: 1. Reauthorize the Rare Pediatric Disease Priority Review Voucher (PPRV) Program The PPRV program has been instrumental in incentivizing the development of therapies for children with rare and life-threatening conditions. Its lapse threatens to slow or halt research that families across the country are counting on. 2. Extend the SBIR/STTR Programs The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs provide crucial early-stage capital for emerging biotech and medtech companies—many of them in Georgia. Without reauthorization, hundreds of innovative small businesses face uncertainty, jeopardizing new therapies, diagnostics, and technologies in the pipeline, 3. Advance PBM Transparency Reforms Greater transparency and accountability within pharmacy benefit manager (PBM) practices are needed to ensure that savings reach patients and employers. Reforming PBM operations is essential to strengthening access and affordability across the healthcare system. A Unified Message from the Life Sciences Community The sign-on letter reflects broad, bipartisan alignment across the national life sciences ecosystem: researchers, entrepreneurs, investors, patient advocates, and state associations all share a common message— these programs underpin America’s global competitiveness and are vital to patients who rely on continued scientific progress. Georgia Life Sciences has shared the letter with members of Georgia’s congressional delegation and will continue engaging with policymakers to emphasize the importance of swift action.
December 7, 2025
Georgia Life Sciences is proud to stand with patient advocates, providers, and employers across the state in urging Congress to take meaningful action on pharmacy benefit manager (PBM) reform. We recently signed on to a joint letter to Georgia’s Congressional Delegation stressing the urgent need for transparency, fair practices, and policies that ensure savings flow directly to patients.
December 4, 2025
Georgia Life Sciences’ CEO, Maria Thacker Goethe shares her perspective on the value of Georgia’s research universities in this month’s issue of Georgia Trend. “Georgia research institutions have felt a very significant impact from the federal rollbacks, specifically in NIH and NSF funding. Thacker Goethe’s message about the impact of research cuts is simple: Disruption shatters the foundational trust researchers have in grant continuity….” To read the full article, click here .
MORE POSTS